Lewis Joseph's Form 4 filing
iTeos Therapeutics, Inc. (ITOS) · filed Aug 25, 2023
- Accession no.
- 0000895345-23-000524
- Filed
- Aug 25, 2023, 9:28 PM ET
- Trade date
- Aug 23, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $5.69M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lewis JosephCIK 0001015747 | Other: See remarks |
| Boxer Asset Management Inc.CIK 0001465836 | Other: See remarks |
| Boxer Capital, LLCCIK 0001465837 | Other: See remarks |
| Davis Aaron I.CIK 0001465914 | Other: See remarks |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 23, 2023 | Common Stock | SSaleDisposed | −34,846 | $14.19F1 | −$494,464.74 | 2,119,212 | Direct | |
| Aug 23, 2023 | Common Stock | SSaleDisposed | −95,516 | $15.63F3 | −$1,492,915.08 | 2,023,696 | Direct | |
| Aug 23, 2023 | Common Stock | SSaleDisposed | −219,638 | $16.87F4 | −$3,705,293.06 | 1,804,058 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.80 to $14.59, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.05 to $15.85, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.50 to $17.04, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Aaron Davis, the CEO of Boxer Capital, LLC, is a director of iTeos Therapeutics, Inc. (the "Issuer"). The reporting persons other than Mr. Davis previously reported ceasing to be subject to Section 16 of the Exchange Act with respect to the Issuer. This filing is being made by those other reporting persons without conceding that they are subject to Section 16 of the Exchange Act with respect to the Issuer.